Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04806620 · ClinicalTrials.gov registry record

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

A clinical trial of Celiac Disease and Post-Acute COVID-19 Syndrome, sponsored by Brain Inflammation Collaborative.

Recruiting
Registry status
10,000
Enrollment target
1
Study location

NCT04806620: Recruiting study of Celiac Disease and Post-Acute COVID-19 Syndrome, sponsored by Brain Inflammation Collaborative.

NCT04806620 is a study of Celiac Disease and Post-Acute COVID-19 Syndrome that is actively recruiting participants, run by Brain Inflammation Collaborative. The registered enrollment target is 10,000 participants, above the 1,563-participant average among 24 other Celiac Disease trials with a reported enrollment target (540% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04806620, a study of Celiac Disease and Post-Acute COVID-19 Syndrome, is actively recruiting participants, sponsored by Brain Inflammation Collaborative.

RECRUITING
Registry status
10,000 participants
Enrollment target
1
Study location

Study Summary

The unhide® Project is a non-interventional, longitudinal research study designed to establish a secure data repository of demographic, health, and lifestyle information from individuals with brain inflammation and related neuroinflammatory conditions. Participants in the United States aged 2 years and older will provide self-reported health data, biometrics, and symptom diaries through the MyDataHelps™ app (branded as unhide® for this study). The goal is to create comprehensive longitudinal profiles to facilitate research into disease subtypes, causes, diagnostics, and potential treatments, as well as to identify potential participants for future optional studies. "Healthy" individuals without brain inflammation are also eligible to participate. The digital health research platform used in this study was originally developed and designed by Solve M.E and was called SolveTogether. The Brain Inflammation Collaborative (BIC) expanded upon Solve M.E.'s work to include related diagnoses, pediatric participants, enhance symptom tracking, and more. BIC and Solve M.E. combined Solve Together and unhide®, to create The unhide® Solve Together Unified Platform in 2025.

Primary Outcome

Collect, collate, clean, and analyze a large, well-characterized longitudinal dataset to investigate causes, disease progression, and potential treatments for complex chronic conditions, including infection-associated chronic diseases such as ME/CFS, Long COVID, PANS/PANDAS, autoimmune diseases, and neuroimmune disorders characterized at least in part by symptoms of neuroinflammation, including fatigue, brain fog, mood and behavioral changes, or other central or peripheral neurological symptoms.

Conditions Studied

Celiac Disease Post-Acute COVID-19 Syndrome ME/CFS Chronic Lyme Disease Celiac Disease in Children Autoimmune Encephalitis Juvenile Rheumatoid Arthritis (JRA) Psoriatic Arthritis (PsA) Ankylosing Spondylitis (AS) Rheumatic Arthritis

Study Locations (1)

Wisconsin

  • Brain Inflammation Collaborative - Delafield

Trial Details

FieldValue
Enrollment Target 10,000 participants
Start Date 2023-07-05
Est. Completion 2030-12-31
Brain Inflammation Collaborative

2 total trials

What NCT04806620 shows while recruiting

NCT04806620 is an observational study that tracks outcomes without assigning an intervention. Its 10,000 participants enrollment target places it among the larger protocols in the corpus, above the 1,563-participant average among 24 other Celiac Disease trials with a reported enrollment target (540% higher).

The record links to 10 conditions, with Celiac Disease appearing as the primary indexed condition, and to 0 interventions.

NCT04806620 reports a single indexed study location in Wisconsin.

Frequently Asked Questions

What is clinical trial NCT04806620 about?

NCT04806620 is a clinical study titled "Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research". The unhide® Project is a non-interventional, longitudinal research study designed to establish a secure data repository of demographic, health, and lifestyle information from individuals with brain inflammation and related neuroinflammatory conditions. Participants in the United States aged 2 years ...

What is the current status of trial NCT04806620?

This trial is currently recruiting. The enrollment target is 10,000 participants. The study started on 2023-07-05. Estimated completion is 2030-12-31.

What conditions does trial NCT04806620 study?

This clinical trial studies the following conditions: Celiac Disease, Post-Acute COVID-19 Syndrome, ME/CFS, Chronic Lyme Disease, Celiac Disease in Children.

Who is sponsoring clinical trial NCT04806620?

This trial is sponsored by Brain Inflammation Collaborative, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04806620 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Celiac Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04806620's enrollment target sits among peer trials

10,000 2nd of 24 the highest of 24 other Celiac Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Celiac Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00160771 · 10,000 participants

    Biomechanics/Motion Analysis Laboratory Data Bank

  • NCT00896935 · 10,000 participants

    Arizona Cancer Center Biospecimen Repository

  • NCT00898235 · 10,000 participants

    Collection of Samples and Clinical Data From Patients With Amyloid Diseases

  • NCT00992303 · 10,000 participants

    Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT04806620

Source: ClinicalTrials.gov NCT04806620, the US trial registry maintained by the National Library of Medicine. NCT04806620 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.